Congress Coverage: ASH 2020 – Focus on Leukemia
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia.
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, New York, NY, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Aaron Logan, MD, PhD
UCSF Health, San Francisco, CA, USA
Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY, USA
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA, USA
REPORT BACKGROUND
- Clinical experts from across the world discussed global perspectives on current treatment strategies and emerging therapies in leukemia derived from ASH 2020 data
- The goal of the expert panel was to critique and debate new evidence in leukemia and gain strategic insight into the most impactful abstracts from the ASH meeting with respect to shaping current research directions and/or changing the scope of practical clinical care
